Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire To Launch Potential Dry Eye Blockbuster After FDA Backs Xiidra

Executive Summary

Securing FDA approval for its novel dry eye treatment Xiidra (lifitegrast) gives Shire PLC a potential blockbuster and key future growth driver whose indication and label are more comprehensive than that of its closest approved rival.

Advertisement

Related Content

Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
GtreeBNT Aims To Validate Business Model Via Licensing Deals
Allergan Sees Growth From New Launches, Not Big M&A
Shire’s Ornskov Says Baxalta Integration on Track, Ups Synergies Forecast

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC096875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel